Smith Jason Drew
General Counsel
Smith Jason Drew has filed 3 SEC Form 4 filings (10 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Sep 9, 2026.
On the most recent filing, Smith Jason Drew is listed as General Counsel at UroGen Pharma Ltd. Inside the rolling window, Smith Jason Drew reported no open-market purchases and 2 open-market sales totaling $212K in URGN. The largest disclosed transaction in the window is a sale of 7,479 URGN shares on Feb 3, 2026, worth $147K.
Companies traded
Other insiders at URGN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$212K
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Sep 8, 2025 | URGN | Sale | $29K |
Frequently asked questions
How many SEC Form 4 filings has Smith Jason Drew made?
Smith Jason Drew has filed 3 SEC Form 4 filings (10 transaction rows) across 1 company since 2025.
Which companies does Smith Jason Drew trade?
Smith Jason Drew has filed SEC Form 4 disclosures for 1 company, including URGN.
When was Smith Jason Drew's most recent SEC Form 4 filing?
Smith Jason Drew's most recent SEC Form 4 filing on Tracefour is dated Sep 9, 2026.
What is Smith Jason Drew's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Smith Jason Drew is listed as General Counsel.
What is Smith Jason Drew's total buy and sell value in the current window?
Inside the rolling retention window, Smith Jason Drew bought $0 and sold $212K based on SEC Form 4 filings.
What was Smith Jason Drew's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 7,479 URGN shares on 2026-02-03, worth $147K, per SEC Form 4 filings.